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delay in diagnosis can mean the difference between a good outcome
and a devastating one. In the field of fetal medicine there are relatively
few proven efficacious interventions. However, in the case fetal infec-
tionwith parvovirus B19, with timely diagnosis andmanagement disas-
ter can often be averted.
Human parvovirus B19 is endemic tomost of the developedworld. It
is known as slapped cheek syndrome or 5th disease (behind measles,
scarlet fever, rubella and Duke's disease). Whilst being the most com-
mon cause of rash in school children it is also a particular concern in
pregnancy. Though the majority of the pregnant population, around
60%, have been exposed to this virus there is still a lot of susceptible
pregnant women [1]. Based on public health England reports there are
over 1000 new cases per annum of laboratory confirmed parvovirus
B19 infections in women of a reproductive age. The incidence of infec-
tion in pregnancy is 1–2% though during an epidemic, which is typically
late winter to early spring, the incidence can be as high as 10%. All preg-
nant women with a new onset generalised rash should undergo testing
for parvovirus B19. As the rash caused by parvovirus B19 is clinically in-
distinguishable from rubella this should also be tested for. Pregnanten access article under the CC BY-NCwomenwith a potentially significant exposure to parvovirus B19 should
also be tested, this is defined as face to face contact with an infected in-
dividual or being in the same room for 15 min or more.
Vertical transmission occurs in 30% of cases. Fetal sequelae includes
miscarriage, non immune hydrops and intrauterine death. This can
occur through inflammation of the placenta, liver and myocardium
but the majority of adverse outcomes come as result of profound fetal
anaemia. Parvovirus B19 has a predilection for rapidly dividing cells
and induces cytotoxic apoptosis and lysis of erythroid progenitor cells.
This makes the fetus particularly susceptible to the virus in the second
trimester when haematopoiesis happens in the liver and there is a 34-
fold increase in red cell mass with a reduction in the life span of the
red blood cells [2].
The risk of fetal loss is stratified based on gestational age. Prior to
20 weeks there is 5–10% loss.
rate, this falls of 0.5% beyond this point.
Should fetal anaemia occur then the treatment is an intrauterine
transfusion (IUT) of red cells. Monitored and transfused appropri-
ately, the perinatal survival rates are as high as 85%. A delay in
diagnosis of fetal anaemia may increase the risk of fetal hydrops
and thrombocytopenia.
Up to 50% of infected womenmay be asymptomatic. Unless women
are aware they have potentially been exposed to parvovirus B19 these-ND license
2 G.J. Waring / Case Reports in Women's Health xxx (2018) e00057cases are then destined to present late so one should always have a high
degree of suspicion when confronted by fetal ascites or pericardial effu-
sions on ultrasound, particularly in combination.
The risk of hydrops is low overall with studies estimating the
incidence of 3–6%, but in those pregnancies that are complicated by
this the rate of fetal loss can be as high as 50% [1]. This is a reflection
that the development of hydrops is a marker of severe anaemia and
late stage disease. De Jong et al. looked at the incidence of severe
neurodevelopmental delay following IUT for anaemia caused by parvo-
virus B19, though their numbers were relatively small, the rate was 11%
and all the fetuses in their study had developed hydrops [3]. The LOTUS
study looked at neurodevelopment outcomes in fetuses that underwent
IUT for haemolytic disease/alloimmunisation. The numbers were much
larger and the study found that severe hydrops independently increased
the odds of neurodevelopment delay, anaemiawithout hydrops did not.
In keeping with the findings or De Jong et al., the rate of severe
neurodevelopmental delay in fetuses affected by hydrops was 12% [4].
These findings suggest that the development of hydrops increases
both mortality and long term morbidity for the fetus.
The rate of parovirus B19 induced fetal thrombocytopenia is esti-
mated to be between 15 and 54%. Like hydrops it appears to be a feature
of late disease in that it is associated with higher severity of anaemia.
Fetal thrombocytopenia is associated with an increased risk of fetal
loss within 48 h of an IUT. The timing here suggests the mechanism of
loss is by fetal haemorrhage as a result of the thrombocytopenia.
Melamed et al. found the rate of severe thrombocytopenia in parvovirus
B19 infected fetuses under going fetal blood samplingwas 38%, of these
fetuses 86% also had fetal hydrops [5].
Thus the challenge in cases at risk of fetal anaemia secondary to
parvovirus B19 is to monitor these pregnancies effectively in order to
intervene in a timely fashion. Monitoring for fetal anaemia can be
done reliably using fetal dopplers. The peak systolic velocity (PSV) of
thewaveform in themiddle cerebral artery (MCA) can detectmoderate
to severe fetal anaemiawith a sensitivity of 100% (95%CI 0.86–1.00) and
a false positive rate of 12%. Previous guidance of themanagement of this
condition had suggested waiting until hydrops was preset prior to
referring on to a fetal medicine specialist [2]. There is thankfully now
a consensus that upon diagnosis of the maternal infection the womanshould be referred to a clinician that is able to perform screening for
fetal anaemia using MCA dopplers and they in turn should either be
able to perform or refer onto a specialist in fetal medicine that can
perform an FBS/IUT in cases of suspected fetal anaemia [6].
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